Legend Biotech Corp. ADR (LEGN): Price and Financial Metrics

Legend Biotech Corp. ADR (LEGN): $42.73

3.38 (+8.59%)

POWR Rating

Component Grades













Add LEGN to Watchlist
Sign Up

Industry: Biotech



in industry

LEGN Stock Price Chart Interactive Chart >

Price chart for LEGN

LEGN Price/Volume Stats

Current price $42.73 52-week high $58.00
Prev. close $39.35 52-week low $30.75
Day low $39.00 Volume 381,200
Day high $42.88 Avg. volume 700,229
50-day MA $39.03 Dividend yield N/A
200-day MA $43.30 Market Cap 6.59B

Legend Biotech Corp. ADR (LEGN) Company Bio

Legend Biotech Corp. is a holding company which engages in the discovery and development of novel cell therapies for oncology and other indications. It carries out its operations through the North America, and China geographical segments. The company was founded in May 2015 and is headquartered in Somerset, NJ.

LEGN Latest News Stream

Event/Time News Detail
Loading, please wait...

LEGN Latest Social Stream

Loading social stream, please wait...

View Full LEGN Social Stream

Latest LEGN News From Around the Web

Below are the latest news stories about Legend Biotech Corp that investors may wish to consider to help them evaluate LEGN as an investment opportunity.

Legend Biotech expects 2021 adj. loss of $335.8M-$364.7M

Legend Biotech (LEGN) has reported preliminary results for 2021, expecting loss of ~$365.3M to $397.4M and adj. loss of $335.8M to $364.7M.As of Dec

Seeking Alpha | February 18, 2022

Legend Biotech Announces Preliminary Results for the Year Ended December 31, 2021

SOMERSET, N.J., February 18, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today in conjunction with an announcement to be issued by Legend Biotech’s majority shareholder, GenScript Biotech Corporation, pursuant to the rules of The Stock Exchange of Hong Kong Limited, announced preliminary, unaudited financial results for the year ended December 31, 2021.

Yahoo | February 18, 2022

Billionaire Ray Dalio Places Bet on 3 “Strong Buy” Stocks

The stock market appears to be making a transition in the these first few months of 2022, from last year’s bullish trend to a slower pace of growth this year. Headwinds are mounting – the pandemic is stubbornly persistent, inflation is high and trending higher, the Fed is getting set to raise interest rates in response, the list goes on – and so it’s natural for retail investors and experts alike to go looking for advice on how to navigate these difficult currents. And one source of advice is the circle of market gurus, the hedge fund experts who have leveraged their insight into multi-billion dollar success.

Michael Marcus on TipRanks | February 16, 2022

FDA Slams Brakes On Legend Biotech''s CAR-T Therapy Trial In Lymphoma Patients

The FDA has instituted a clinical hold on Legend Biotech Corporation''s (NASDAQ: LEGN ) Phase 1 trial for LB1901. LB1901 is the company''s investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy targeting malignant CD4+ T-cells for relapsed or refractory T-cell lymphoma (TCL). The … Full story available on Benzinga.com

Benzinga | February 15, 2022

Legend Biotech slips after FDA clinical hold on blood cancer study for CAR-T therapy

Legend Biotech (LEGN) is trading ~6% lower in the pre-market on Tuesday after the company announced that the U.S Food and Drug Administration ((FDA)) imposed a clinical hold on its Phase…

Seeking Alpha | February 15, 2022

Read More 'LEGN' Stories Here

LEGN Price Returns

1-mo 7.77%
3-mo 11.22%
6-mo -21.03%
1-year 8.53%
3-year N/A
5-year N/A
YTD -8.32%
2021 65.52%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6264 seconds.